![]() |
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
For many years, the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has reached out to its international regulatory colleagues. Since 2005, CDER has held the CDER Forum for International Drug Regulatory Authorities every spring and fall so international regulators can learn first-hand how CDER organizes the drug review process and carries out its mission of ensuring the safety and efficacy of human drug products in the United States.
The interest in these "live" meetings has grown exponentially with FDA working in harmonization with countries around the world. Many more people than can be accommodated at these small meetings want to learn about the science, technology, regulations and processes CDER uses to accomplish its complex and challenging work. To respond to this great interest, the Center has developed "CDER World."
"CDER World," is an ever-growing compendium of information about how CDER carries out its mission, adapts to new legislative initiatives, and initiates directions in regulatory science to improve the public health.
For more information, please visit: CDER World
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).


